Talk about the potential mega-merger between Pfizer (NYSE: PFE) and Allergan (NYSE: AGN) – the biggest proposed deal in pharma history – and whether it will or won’t happen, has inevitably gained enormous attention in the wider world.
But a lot more went on in the world of mergers and acquisitions in pharma and biotech in March.
The month began with news that French orphan oncology Onxeo (Euronext Paris: ONXEO) had agreed to buy DNA Therapeutics, a privately-held, clinical-stage French biopharmaceutical company, for its signal-interfering DNA (siDNA) repair technology, which is directed at overcoming cancer resistance mechanisms.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze